At ASCO 2020 meeting, the new final survival results of the SPARTAN study were reported. When we look at overall survival in SPARTAN, the use of apalutamideprolongs survival from 60 months to 74 months – that is a 14-month survival advantage, with a hazard ratioof 0.78. Earlier reports have shown significant advantages in reduction of ...

#Siste magasin

BestPractice Nordic

Nr. 2 • juni 2020
1. Årgang
  • Diabetes type 2 og hjertesykdom
  • Pneumokokkvaksinering
  • Prevensjon